CD8A and neoplasm: Combining erastin and defactinib significantly remodeled the pancreatic morphology towards the normal, and shifted the suppressive immune microenvironment into a “hot” state by promoting the intratumoral infiltration of CD8+ T cells and decreasing Treg lymphocytes and intratumoral type II macrophages, which plays a crucial role in arousing anti-tumor activity.